Home » Stocks » SEER

Seer, Inc. (SEER)

Stock Price: $50.80 USD 0.07 (0.14%)
Updated Apr 23, 2021 10:46 AM EDT - Market open
Market Cap 671.41M
Revenue (ttm) 656,000
Net Income (ttm) -32.78M
Shares Out 13.22M
EPS (ttm) -2.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 23
Last Price $50.80
Previous Close $50.73
Change ($) 0.07
Change (%) 0.14%
Day's Open 51.05
Day's Range 50.40 - 51.95
Day's Volume 43,146
52-Week Range 38.37 - 86.55

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

REDWOOD CITY, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report fina...

1 week ago - GlobeNewsWire

Seer Proteographâ„¢ Product Suite combined with SCIEX mass spectrometry technology to provide unbiased, deep proteomics workflows for labs of all types Seer Proteographâ„¢ Product Suite combined with SCIEX ...

3 weeks ago - GlobeNewsWire

Added Salk Institute as collaboration customer and SCIEX as new commercial partner Added Salk Institute as collaboration customer and SCIEX as new commercial partner

3 weeks ago - GlobeNewsWire

REDWOOD CITY, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report fina...

1 month ago - GlobeNewsWire

Lee Ainslie (Trades, Portfolio), the founder and CEO of Maverick Capital, recently disclosed the firm's portfolio changes for the fourth quarter of 2020, which ended on Dec. 31.

Other stocks mentioned: AMAT, FLT, MGM
1 month ago - GuruFocus

REDWOOD CITY, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participa...

1 month ago - GlobeNewsWire

REDWOOD CITY, Calif. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the closing of an underwritten publ...

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the pricing of an underwritten publi...

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the commencement of a proposed under...

2 months ago - GlobeNewsWire

Combination of Thermo Fisher's market leading Orbitrap mass spectrometer portfolio with Seer Proteographâ„¢ Product Suite to expand availability of end-to-end proteomics in new markets Combination of Ther...

3 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid ...

3 months ago - GlobeNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: CAR, ARDX, CNNE, MPLN, SBTX
4 months ago - Benzinga

REDWOOD CITY, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable pr...

4 months ago - GlobeNewsWire

The hot category of initial public offerings in the biotechnology sector continues, with two set to trade Friday: Seer and Silverback Therapeutics. Both priced above their estimated range.

Other stocks mentioned: SBTX
4 months ago - Investors Business Daily

REDWOOD CITY, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable pr...

4 months ago - GlobeNewsWire

About SEER

Seer, Inc. aims to enable exceptional scientific outcomes by commercializing transformative products for researchers to unlock deep, unbiased biological information. Our initial product, the Proteograph Product Suite (Proteograph), will leverage our proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome. Our Proteograph Product Suite is an integrated solution that is comprised of consumables, an automation instrument and software. Our Proteograph provides an easy-to-use wo... [Read more...]

Industry
Biotechnology
IPO Date
Dec 4, 2020
CEO
Omid Farokhzad
Employees
60
Stock Exchange
NASDAQ
Ticker Symbol
SEER
Full Company Profile

Financial Performance

In 2020, Seer, Inc's revenue was $656,000, an increase of 465.52% compared to the previous year's $116,000. Losses were -$32.78 million, 104.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Seer, Inc stock is "Buy." The 12-month stock price forecast is 63.67, which is an increase of 25.33% from the latest price.

Price Target
$63.67
(25.33% upside)
Analyst Consensus: Buy